Guard Therapeutics International AB (DPHA) Stock Statistics & Valuation Metrics

Guard Therapeutics International AB has a market cap or net worth of SEK 50.56M. The enterprise value is -SEK 1.84M.

Market Cap

SEK 50.56M

Enterprise Value

-SEK 1.84M

Guard Therapeutics International AB has 44,588,066 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

44,588,066

Owned by Insiders

―

Owned by Institutions

―

Guard Therapeutics International AB’s return on equity (ROE) is -2.68 and return on invested capital (ROIC) is -244.62%.

Return on Equity (ROE)

-2.68

Return on Assets (ROA)

-2.01

Return on Invested Capital (ROIC)

-244.62%

Return on Capital Employed (ROCE)

-2.45

Revenue Per Employee

0

Profits Per Employee

-9.07M

Employee Count

12

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Guard Therapeutics International AB is -0.36. Guard Therapeutics International AB’s PEG ratio is -0.00.

PE Ratio

-0.36

PS Ratio

0.00

PB Ratio

0.81

Price to FCF

-0.36

Price to Operating Cash Flow

-0.36

PEG Ratio

-0.00

In the last 12 months, Guard Therapeutics International AB had revenue of 0 and earned -108.85M in profits. Earnings per share was -6.04.

Revenue

0

Gross Profit

0

Operating Income

-107.74M

Pretax Income

-108.85M

Net Income

-108.85M

EBITDA

-107.74M

Earnings Per Share (EPS)

-6.04

In the last 12 months, operating cash flow was -82.34M and capital expenditures 0, giving a free cash flow of -82.34M billion.

Operating Cash Flow

-82.34M

Free Cash Flow

-82.34M

Free Cash Flow per Share

-4.08

Guard Therapeutics International AB pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-278.13%

Earnings Yield

-273.55%

Beta

0.48

52-Week Price Change

-30.85%

50-Day Moving Average

1.22

200-Day Moving Average

1.40

Relative Strength Index (RSI)

49.41

Average Volume (3m)

33.02K

Guard Therapeutics International AB upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 20, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

―

Guard Therapeutics International AB as a current ratio of 5.36, with Debt / Equity ratio of 0.00%

Current Ratio

5.36

Quick Ratio

5.36

Debt to Market Cap

0.00

Net Debt to EBITDA

0.46

Interest Coverage Ratio

-48.25

In the past 12 months, Guard Therapeutics International AB has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Guard Therapeutics International AB EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.14.

EV to Sales

0.00

EV to EBITDA

0.14

EV to Free Cash Flow

0.14

EV to Operating Cash Flow

0.14

Guard Therapeutics International AB has SEK 40.99M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 40.99M billion.

Cash & Marketable Securities

SEK 40.99M

Total Debt

SEK 0.00

Net Cash

SEK 40.99M

Net Cash Per Share

SEK 0.92

Tangible Book Value Per Share

SEK 1.81

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Guard Therapeutics International AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

―

EPS Growth Forecast

70.76%

Smart Score

―

AI Score

47